

## Investor Relations | Hologic

### Hologic to Participate in Three Investor Conferences

PR Newswire  
BEDFORD

BEDFORD, Mass., Nov. 10, 2010 [/PRNewswire-FirstCall/](#) -- Hologic, Inc. (Nasdaq: HOLX) today announced that company management will participate in the following conferences:

- Rob Cascella, President and Chief Executive Officer, will present at the J.P. Morgan SMid Conference in New York City on Thursday, December 2, 2010, at 4:30 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at [www.hologic.com/investors-overview](http://www.hologic.com/investors-overview). An archive of the presentation will be available for replay following the conference.
- Glenn Muir, Executive Vice President and Chief Financial Officer, will host investor meetings at the Lazard Capital Markets Medical Technology Corporate Access Day in Denver on Thursday, December 2, 2010. Management will not be presenting at this conference and therefore there will be no webcast.
- Deborah Gordon, Vice President of Investor Relations, will host investor meetings at the Nasdaq OMX 25th Investor Program in London on Tuesday, December 7, 2010. Management will not be presenting at this conference and therefore there will be no webcast.

#### About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit [www.hologic.com](http://www.hologic.com).

#### Contact:

Deborah Gordon  
Vice President, Investor Relations  
Hologic, Inc.  
[deborah.gordon@hologic.com](mailto:deborah.gordon@hologic.com)  
(781) 999-7716

SOURCE Hologic, Inc.

---

<https://investors.hologic.com/news?item=27>